Biotech appeared to be a defensive play. |
Biotech investing is no longer a pie-in-the-sky game. |
Frankly, it really is state-of-the-art. There's only a handful of these things in the United States. There's some bigger ones, maybe some more impressive ones, but that facility they have there is terrific, no question about it. |
If the once-a-month data were equivalent, it would have been a home run. Efficacy is what primarily drives the hepatitis C market. |
Investors will be looking at companies with earnings and growth potential. They're not going to wait two years for drug discovery and four years for product development. And that leaves a lot of biotech companies off the radar. |
The timing of this announcement is very, very fortuitous. |
They are at the starting line now. They have all the bioreactors in there. The pipes are connected. All the switches work. Now they have to get clearance. |
Typically, they are faster to generate revenue and, hopefully, faster to profitability. |